Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.39 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9340592 | 0.88 | CYP2D6 (0.38) | ALDH1A1KMT2ATDP1MEN1TSHR | |
| SCHEMBL14055530 | 0.86 | ALDH1A1 (0.34) | ALDH1A1KMT2ATDP1MEN1TSHR | |
| SCHEMBL16704254 | 0.83 | ALDH1A1 (0.41) | ALDH1A1KMT2ATDP1MEN1LMNA | |
| SCHEMBL27835341 | 0.82 | CES2 (0.36) | ALDH1A1KMT2AMEN1HPGDLMNA | |
| SCHEMBL14054893 | 0.82 | CYP1A1 (0.42) | ALDH1A1KMT2AMEN1CYP3A4HPGD | |
| SCHEMBL5600046 | 0.78 | ALDH1A1 (0.43) | ALDH1A1KMT2ATDP1MEN1TSHR | |
| SCHEMBL8401591 | 0.77 | ALDH1A1 (0.40) | ALDH1A1KMT2ATDP1MEN1TSHR | |
| SCHEMBL14054810 | 0.76 | KMT2A (0.36) | ALDH1A1KMT2AMEN1HPGDLMNA | |
| SCHEMBL660134 | 0.75 | TDP1 (0.35) | ALDH1A1KMT2ATDP1TSHRCYP3A4 | |
| SCHEMBL30711864 | 0.75 | TDP1 (0.35) | ALDH1A1KMT2ATDP1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2022047230-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-2714661-B1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-30 | — | — | EP | disclosed |
| CN-102482203-B | Carbocyclic GLYT1 receptor antagonists | HOFFMANN LA ROCHE | 2015-06-03 | — | — | CN | disclosed |
| US-9045389-B2 | Biphenyl derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-02 | — | — | US | disclosed |
| EP-2714647-B1 | BIPHENYL DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-29 | — | — | EP | disclosed |
| EP-2470498-B1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-02-11 | — | — | EP | disclosed |
| EP-2470498-B1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-02-11 | — | — | EP | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-5739083-A | LOW IN TOXICITY AND PERSISTENCE | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0802191-A1 | PYRAZOLE DERIVATIVES AND INSECTICIDAL COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENT | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-10-22 | — | — | EP | disclosed |
| US-5380865-A | Halogen substituents | MAY & BAKER LIMITED (GB) | 1995-01-10 | — | — | US | disclosed |
| EP-0396987-B1 | Nuclear fluorinated trifluoromethylbenzaldehydes | BAYER AG (DE) | 1994-06-15 | — | — | EP | disclosed |
| US-5206257-A | Controlling plant nematodes, helminth, protozoa | MAY & BAKER LIMITED (GB) | 1993-04-27 | — | — | US | disclosed |
| US-5041683-A | Nuclear-fluorinated trifluoromethylbenzaldehydes | BAYER AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0396987-A2 | Nuclear fluorinated trifluoromethylbenzaldehydes | BAYER AG (DE) | 1990-11-14 | — | — | EP | disclosed |
| EP-0283173-A1 | Pesticidal method using 2-phenylimidazole derivatives | RHONE-POULENC AGRICULTURE LIMITED (GB) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | GRIA1, GLRA1, GRIA3 | ALDH1A1 1488/4885KMT2A 836/4885TDP1 1106/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | ALDH1A1 2449/4885KMT2A 36/4885TDP1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.